Valeant Pharma (VRX) Gains on Rare Upgrade at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St climbs after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Deutsche Bank Upgrades Valeant Pharmaceuticals (VRX) to Buy
March 5, 2018 1:53 AM EST(Updated - March 5, 2018 4:12 AM EST)
(updated to add price target and analyst comment)
Deutsche Bank upgraded Valeant Pharmaceuticals (NYSE: VRX) from Hold to Buy, price target $20.00.
Analyst Gregg Gilbert is incremental more positive on the stock given the set up... More
